Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novartis agreed Thursday to acquire Mariana Oncology in a deal worth up to $1.75 billion, the latest move by the Swiss drugmaker to expand its radioligand…
Novartis is continuing its radiopharmaceutical roll with a $1.75 billion deal to buy Mariana Oncology. The acquisition adds MC-339, an…
Novartis has entered into an agreement to acquire Mariana Oncology for up to $1.75 billion, a move designed to strengthen its radioligand therapy pipeline.…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Novartis acquired Mariana Oncology for $1.0B upfront plus up to $750M in milestones (total $1.75B), expanding its radioligand therapy (RLT) pipeline and infrastructure with MC-339 (an actinium-based RLT in small cell lung cancer) plus earlier RLT programs across solid tumors. Announced May 2, 2024, the all-cash acquisition completed in Q2 2024 and is reported as a completed business combination in Novartis's half-year 2024 financials (cash ~$1.1B net of cash acquired, plus contingent milestone consideration). The deal reinforces Novartis's leading radiopharmaceuticals position behind Pluvicto and Lutathera.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Mariana Oncology Inc. (this deal) | 2024 | $1.8B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2024 deals · Novartis AG deals · Oncology deals